Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Binah Capital Group, Inc. stock logo
BCG
Binah Capital Group
$2.13
+5.4%
$2.14
$1.71
$6.55
$33.54M0.43465,874 shs25,681 shs
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.07
+1.9%
$47.45
$41.61
$63.33
$95.99B0.3612.80 million shs16.47 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Binah Capital Group, Inc. stock logo
BCG
Binah Capital Group
+2.02%+3.06%-2.88%-15.83%-64.69%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+1.48%-1.09%-3.06%-4.21%+14.47%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Binah Capital Group, Inc. stock logo
BCG
Binah Capital Group
0.3429 of 5 stars
0.03.00.00.03.00.00.0
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
4.9012 of 5 stars
3.23.04.24.03.13.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Binah Capital Group, Inc. stock logo
BCG
Binah Capital Group
0.00
N/AN/AN/A
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.32
Hold$57.6920.02% Upside

Current Analyst Ratings Breakdown

Latest CNIC, BCG, MONY, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$36.00 ➝ $34.00
4/25/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/25/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/23/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$70.00 ➝ $68.00
4/22/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$55.00 ➝ $55.00
4/22/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Binah Capital Group, Inc. stock logo
BCG
Binah Capital Group
$172.37M0.21N/AN/A($0.02) per share-106.50
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.30B2.03$6.00 per share8.01$8.08 per share5.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Binah Capital Group, Inc. stock logo
BCG
Binah Capital Group
-$4.56M-$0.12N/AN/A-1.10%-192.35%-2.91%8/21/2025 (Estimated)
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-$8.95B$2.6718.007.892.4311.38%87.62%15.98%7/31/2025 (Estimated)

Latest CNIC, BCG, MONY, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2025Q2 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.53N/AN/AN/A$11.32 billionN/A
5/15/2025Q1 2025
Binah Capital Group, Inc. stock logo
BCG
Binah Capital Group
N/A$0.06N/A$0.06N/AN/A
4/24/2025Q1 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.50$1.80+$0.30$1.21$10.77 billion$11.20 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Binah Capital Group, Inc. stock logo
BCG
Binah Capital Group
N/AN/AN/AN/AN/A
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.485.16%N/A92.88%17 Years

Latest CNIC, BCG, MONY, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/17/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.625.25%7/3/20257/3/20258/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Binah Capital Group, Inc. stock logo
BCG
Binah Capital Group
N/A
0.41
0.41
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.65
1.28
1.17

Institutional Ownership

CompanyInstitutional Ownership
Binah Capital Group, Inc. stock logo
BCG
Binah Capital Group
4.97%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%

Insider Ownership

CompanyInsider Ownership
Binah Capital Group, Inc. stock logo
BCG
Binah Capital Group
1.86%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Binah Capital Group, Inc. stock logo
BCG
Binah Capital Group
13016.60 million16.29 millionN/A
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
34,1002.04 billion2.03 billionOptionable

Recent News About These Companies

Research Analysts Offer Predictions for BMY Q2 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Binah Capital Group stock logo

Binah Capital Group NASDAQ:BCG

$2.13 +0.11 (+5.45%)
Closing price 04:00 PM Eastern
Extended Trading
$2.13 +0.00 (+0.23%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Binah Capital Group, Inc., together with its subsidiaries, operates in the wealth management industry. The company provides access to stock, bond, exchange-traded fund, and options execution services; and research, compliance, supervision, and accounting and related services for financial advisors. It also offers mutual funds and insurance products, as well as alternative investments, such as non-traded real estate investment trusts, unit trusts, and fixed and variable annuities. The company was founded in 2016 and is headquartered in Albany, New York. Binah Capital Group, Inc. operates as a subsidiary of MHC Securities, LLC.

Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$48.06 +0.90 (+1.90%)
Closing price 03:59 PM Eastern
Extended Trading
$48.08 +0.02 (+0.03%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.